Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts
- 12 November 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 34 (1), 24-40
- https://doi.org/10.1007/s10637-015-0303-x
Abstract
Coibamide A is a cytotoxic lariat depsipeptide isolated from a rare cyanobacterium found within the marine reserve of Coiba National Park, Panama. Earlier testing of coibamide A in the National Cancer Institute in vitro 60 human tumor cell line panel (NCI-60) revealed potent anti-proliferative activity and a unique selectivity profile, potentially reflecting a new target or mechanism of action. In the present study we evaluated the antitumor activity of coibamide A in several functional cell-based assays and in vivo. U87-MG and SF-295 glioblastoma cells showed reduced migratory and invasive capacity and underwent G1 cell cycle arrest as, likely indirect, consequences of treatment. Coibamide A inhibited extracellular VEGFA secreted from U87-MG glioblastoma and MDA-MB-231 breast cancer cells with low nM potency, attenuated proliferation and migration of normal human umbilical vein endothelial cells (HUVECs) and selectively decreased expression of vascular endothelial growth factor receptor 2 (VEGFR2). We report that coibamide A retains potent antitumor properties in a nude mouse xenograft model of glioblastoma; established subcutaneous U87-MG tumors failed to grow for up to 28 days in response to 0.3 mg/Kg doses of coibamide A. However, the natural product was also associated with varied patterns of weight loss and thus targeted delivery and/or medicinal chemistry approaches will almost certainly be required to improve the toxicity profile of this unusual macrocycle. Finally, similarities between coibamide A- and apratoxin A-induced changes in cell morphology, decreases in VEGFR2 expression and macroautophagy signaling in HUVECs raise the possibility that both cyanobacterial natural products share a common mechanism of action.Keywords
Funding Information
- American Brain Tumor Association (Discovery Grant)
- American Foundation for Pharmaceutical Education (Pre-Doctoral Fellowship)
This publication has 47 references indexed in Scilit:
- Coibamide A Induces mTOR-Independent Autophagy and Cell Death in Human Glioblastoma CellsPLOS ONE, 2013
- Mechanisms of Glioma-Associated NeovascularizationThe American Journal of Pathology, 2012
- Identifying mechanism-of-action targets for drugs and probesProceedings of the National Academy of Sciences of the United States of America, 2012
- Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor ActivityACS Medicinal Chemistry Letters, 2011
- Evolved Diversification of a Modular Natural Product Pathway: Apratoxins F and G, Two Cytotoxic Cyclic Depsipeptides from a Palmyra Collection ofLyngbya bouilloniiChemBioChem, 2010
- Kinetic Cell-Based Morphological Screening: Prediction of Mechanism of Compound Action and Off-Target EffectsCell Chemical Biology, 2009
- Cyclodepsipeptide toxin promotes the degradation of Hsp90 client proteins through chaperone-mediated autophagyThe Journal of cell biology, 2009
- Coibamide A, a Potent Antiproliferative Cyclic Depsipeptide from the Panamanian Marine Cyanobacterium Leptolyngbya sp.Journal of the American Chemical Society, 2008
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- Mechanism of Blebbistatin Inhibition of Myosin IIJournal of Biological Chemistry, 2004